Navigation Links
ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
Date:2/9/2009

FREDERICK, Md., Feb. 9 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the continued development of their small molecule inhibitor of HIV-1 at the 16th CROI meeting held this week in Montreal. The presentation highlighted the advanced development of ImQuest's lead HIV pyrimidinedione inhibitor, IQP-0410. The pyrimidinediones are highly potent inhibitors of HIV, exhibiting a dual mechanism of action which includes targeting virus entry and reverse transcription. The data presented demonstrate that IQP-0410 is well tolerated and safe with plasma drug concentrations 10-20-fold greater than those required for complete suppression of HIV replication at 24-hours following oral administration. Thus, IQP-0410 can be dosed once per day, and possesses a highly positive safety profile which suggests it will be amenable for use in women of child bearing years. Nick Kaludov, Ph.D., Director of Scientific Operations presented the new findings which also included metabolism, safety pharmacology, and genotoxicology evaluations. The studies included ImQuest co-authors Karen Watson, M.S. and Robert W. Buckheit, Jr., Ph.D.

"The data presented today indicate that IQP-0410 may represent a next generation HIV drug with a highly unique mechanism of action and an excellent safety profile," said Dr. Buckheit, Executive Vice President and Chief Scientific Officer. "We look forward to our upcoming clinical trial and believe that IQP-0410 will be an attractive new addition to existing antiretroviral therapies for HIV infection."

ImQuest recently submitted an Investigational New Drug application to the FDA to initiate human clinical trials with IQP-0410 and is concurrently developing a new generation pyrimidinedione with an enhanced barrier to resistance from among the series of pyrimidinediones.

ImQuest Life Sciences (www.ImquestLS.com<
'/>"/>

SOURCE ImQuest Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
2. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
3. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
8. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
9. Arpida Presents Preclinical Data on AR-2474 at ICAAC
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 ... BVXV) today announced the intent of the National Institute of ... Institutes of Health (NIH) within the Department of Health and ... to be held in the United States ... use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... in manufacturing equipment, to creating professional commercial video content, to analysis of athletic ... of fascinating events that go by too quickly to process with the naked ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... fear for a doctor may be losing a patient, but a ... hospital, there are hundreds of supplies to keep track of and ... leaves doctors rooting around in the supply closet for an IV ... a defibrillator. , ,According to Barry Chaiken, associate chief medical officer ...
... Wisconsin Governor Jim Doyle ventured into what could ... controversial stem cell patent of the Wisconsin Alumni Research ... cell research, Doyle went after his Republican opponent, Congressman ... human embryonic stem cell research. , ,Firing back, Green charged ...
... of announcements from hard disk drive stalwart Seagate. After all, this ... years - and disk storage is, as everyone knows, a rather ... someone has packed another gigabyte of magnetic bits onto the head ... pay much attention to - or even see - the announcement ...
Cached Biology Technology:RFID system aids hospital in tracking assets 2RFID system aids hospital in tracking assets 3Doyle, Green exchange stem cell salvos 2Doyle, Green exchange stem cell salvos 3Doyle, Green exchange stem cell salvos 4Digital Media Superstar: Seagate? 2Digital Media Superstar: Seagate? 3
(Date:8/25/2015)... and BELLEVUE, Wash. , Aug. 25, ... robotic systems, announced today it will unveil its "Guardian ... (UGV), at the National Tactical Officers Association Conference on ... The Guardian S is the first-ever commercially available energetically ... of research and in-field trials and is protected by ...
(Date:8/24/2015)... , Aug. 24, 2015  Based on its recent ... DERMALOG with the 2015 African Biometrics Company of the Year ... achieved substantial commercial success in Africa . ... , where it has implemented one of the largest biometric ... as well as the Central Bank of Nigeria ...
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... reporting an "important step" toward development of a universal ... blood to match donor and recipient before transfusions. A ... from antibodies that could trigger a potentially fatal immune ... appears in the ACS journal, Biomacromolecules . ...
... Society for Clinical and Economic Aspects of Osteoporosis ... (IOF) have announced that Professor Gerard Karsenty of ... awarded the first Herbert A. Fleisch ESCEO-IOF Medal. ... work contributed to the development of the field ...
... took nearly a decade before University of Maryland researchers were ... used in the 2001 deadly letter attacks. But now, they ... have published the first account of the pioneering work, which ... investigators a way to "fingerprint" bacteria. The current online ...
Cached Biology News:Inaugural Herbert A. Fleisch ESCEO-IOF Medal is awarded to Professor Gerard Karsenty 2Now, the story can be told - how scientists helped ID 'Amerithrax' 2Now, the story can be told - how scientists helped ID 'Amerithrax' 3
...
... TFT color screen, without Camera • ... with 8.0 mega pixel resolution. It is computer ... View image from large 5.6" TFT color liquid ... suitable to capture image for fluorescent gels, colorimetric ...
... RapidTrace SPE Workstation is a modular, highly ... platform. Utilizing 1ml or 3ml industry standard ... to 100 samples in less than two ... with 10 cartridges, and up to 10 ...
... Small space saving design - ideal for personal use ... , - 3D gyratory action SSM3 , - ... control and built-in timer , Optional tier system available ... where gentle mixing is required, either on the bench ...
Biology Products: